Narrative review evaluates clinical outcomes of platelet-rich plasma in recurrent pregnancy loss, highlighting the need for biomarker-guided patient selection.
Key Points
Critically evaluate the biological rationale and clinical evidence for platelet-rich plasma in recurrent pregnancy loss and establish a precision medicine framework for patient selection.
Narrative synthesis of clinical and mechanistic literature regarding platelet-rich plasma applications in recurrent pregnancy loss, thin endometrium, and recurrent implantation failure.
Evaluation of biological mechanisms encompassing vascular endothelial growth factor-mediated angiogenesis, stromal proliferation, and immune system modulation.
Platelet-rich plasma enhances endometrial regeneration and regulatory T-cell activity while promoting angiogenesis and regulating key implantation genes such as LIF and HOXA10.
Indirect clinical evidence from recurrent implantation failure and thin endometrium demonstrates improved endometrial thickness and pregnancy rates, but direct recurrent pregnancy loss data remain insufficient to confirm reduced miscarriage rates.